| Wednesday, May 6, 2026 | ||
|---|---|---|
| 8:30 AM - 11:30 AM | Machine Perfusion: Workshop 1 | |
| 8:30 AM - 12:00 PM | Elevating the Quality of Liver Transplant Care | Pushing the Boundaries: AHP Management of Complicated Pre- and Post-Liver Transplant Patients Hidden Dangers: Herbal and Dietary Supplement–Induced Hepatotoxicity Setting the Standard for Prehabilitation Before Liver Transplantation Elevating the Standards in Managing Nonadherence After Liver Transplantation How to Manage a MASH/MASLD Patient Before and After Liver Transplantation Utilizing Living Donors for Liver Transplantation in CRLM and CCA Patients Optimizing Liver Transplantation: Utilizing Machine Perfusion for Longer Periods of Time—How Far Can We Go? |
| 8:30 AM - 12:00 PM | Special Symposium: Cross-Straits Medicine Exchange Association (CSMEA) | Presentations: Satellite Symposium: Chinese Experience and Clinical Practice of Tacrolimus in Perioperative and Long-Term Management After Liver Transplantation 30 Years of Evidence-Based Medicine for Tacrolimus and Exploration of Clinical Practice in China
Session I :
Precision Stratification in Transplant Oncology: Biomarkers and Personalized Therapy Cutting-edge Exploration and Translational Research in Transplant Oncology Modulating the Post-Transplant Milieu: The Pivotal Function of MDSCs in Liver Transplant Immunology and Oncology AI-enabled Multi-omics Integration for Transplant Oncology: Predicting Recurrence and Guiding Precision Therapy in HCC Panel Discussion and Q&A
Session II: Ex Vivo Liver Resection and Autologous Liver Transplantation Cutting-edge Exploration of Robot-assisted and Laparoscopic Liver Transplantation Techniques Precision Surgery Empowering Innovative Techniques for Split Liver Transplantation Precision Technology Practice in Pediatric Liver Transplantation Downstaging before LT for HCC |
| 9:30 AM - 12:00 PM | Special Symposium: Riffs & Grooves in Transplant Hepatology — Compilations & THINK Business | Part 1: Riffs and Grooves in Transplant Hepatology Achieving Weight “Nirvana”: Medication Management of Obesity Pre- or Post-Transplant “Jane’s Addiction”: Food and Alcohol Management Pre- and Post-Transplantation “Pearls n’ Jams” of Bariatric Surgery in Liver Transplant Candidates: Does Timing and ALD Status Matter? Discussion & Global Projects to Move the Practice Forward Long-Term Management of the Liver Transplant Recipient: Global Survey Results A Global Stance on Transplant Hepatology Training Updates from Regions on Ongoing Projects, Membership, and Initiatives |
| 10:00 AM - 12:00 PM | Drug-Induced Liver Injury (DILI) in Liver Transplantation: Before, After, and Emerging Tools for Assessment and Risk Stratification |
Liver Allograft Dysfunction in Patients Transplanted Following Neoadjuvant Treatment for Hepatocellular Carcinoma Unexplained Liver Allograft Dysfunction Despite Adequate Immunosuppression Review of Extrahepatic and Hepatic Complications of Immunosuppressive Drugs in Liver Transplant Patients
Pathway 2: DILI Histopathological and Emerging Diagnostic Tools in Liver Transplantation Moderated by: Zongming Eric Chen & Mina Komuta
Pathway 2: DILI Histopathological and Emerging Diagnostic Tools in Liver Transplantation Panel Discussion |
| 11:30 AM - 1:15 PM | Machine Perfusion: Workshop 1 & 2 Lunch Symposium | Liver Perfusion for Logistics: Is It Safe? Liver Assessment During Machine Perfusion—Current and Future Perspectives Combined Perfusion Techniques: What Is the Right Mix? The Future of Machine Perfusion: Long-Term Perfusion and Graft Repair |
| 1:00 PM - 6:00 PM | Novel Strategies to Improve the Outcome of Liver Transplantation: Part I, Part II, and Part III | Part I: Progress in Medical Management
The Cure or Quiet Riot: Immunosuppression Minimization and Non-Invasive Testing New Kids on the Block for Infectious Prophylaxis and Management Post Liver Transplantation Cheap Trick: Applying Lessons Learned from Kidney Transplant Immunosuppression Studies Dire Straits: Immunosuppression Management Through Immunotherapy to Improve Access and Outcomes to Anti-Cancer Therapies
Part II: Advances in the Treatment of Acute Liver Failure
Prognostic Criteria and Biomarkers in Acute Liver Failure: Recent Advances and Emerging Insights Plasma Exchange in Acute Liver Failure: Bridging Support to Recovery Reviving the Failing Liver: The Role of APOLT in Acute Liver Failure Auxiliary Liver Xenografts for Acute Liver Failure—From Concept to Clinical Reality?
Part III: Redefining the Boundaries of Cancer Care
Expanding Liver Transplant Criteria in Patients with HCC: Drawing the Line Individualizing Downstaging Modalities in Patients with HCC: How Do I Choose the Best One? Designing the Ideal Pathway: The Peritransplant Journey for Patients with Colorectal Liver Metastasis “Don’t Stop Believing”: LT for Neuroendocrine Metastasis—Has It Lived Up to Its Promise? |
| 1:15 PM - 4:30 PM | Machine Perfusion: Workshop 2 | |
| 2:00 PM - 3:45 PM | TEE Workshop: Session 1 | |
| 2:00 PM - 3:45 PM | High-Fidelity Simulation: Session 1 | |
| 4:15 PM - 6:00 PM | TEE Workshop: Session 2 | |
| 4:15 PM - 6:00 PM | High-Fidelity Simulation: Session 2 | |
| 6:30 PM - 7:30 PM | Opening Ceremony | |
| 7:30 PM - 8:30 PM | Welcome Reception | |
| Thursday, May 7, 2026 | ||
| 7:00 AM - 8:00 AM | Meet the Expert 2: Downstaging Hepatocellular Carcinoma | Loco-Regional Downstaging Systemic Downstaging |
| 7:00 AM - 8:00 AM | Meet the Expert 1: From Contraindication to Indication—Liver Transplantation for Colorectal Liver Metastases | Liver Transplantation for Colorectal Liver Metastasis: European Experiences Liver Transplantation for Colorectal Liver Metastasis: American Experiences |
| 7:00 AM - 8:00 AM | Vanguard Committee Debate | Debate 1: Liver Transplant for Acute Alcoholic Hepatitis or 6 Months Abstinence—Justifiable Cure or Controversial Gamble Debate 2: Measuring Meaningful Outcomes in Liver Transplantation—This House Believes Graft and Patient Survival Are No Longer Enough to Define Success Debate 3: This House Believes That Preventing Burnout in Transplant Professionals Is Primarily the Responsibility of Healthcare Organizations Rather Than Individual Resilience |
| 7:00 AM - 8:00 AM | Meet the Expert 4: Beyond the VET Trace—A Case-Based Approach to Fibrinolysis Management in Liver Transplant | Beyond the VET Trace: A Case-Based Approach to Fibrinolysis Management in Liver Transplant Perioperative Management of Severe Hepatopulmonary Syndrome |
| 7:00 AM - 8:00 AM | Meet the Expert 5: Ischemia-Free Liver Transplantation | Ischemia-Free Liver Transplantation: From Experimental Concept to Clinical Reality Ischemia-Free Implantation: Surgical Standardization, Pitfalls, and Global Adoption |
| 7:00 AM - 8:00 AM | Vanguard Flash e-Poster : Session 1 |
CD40L-Target Nanoparticles Co-Delivering Sirolimus and CD28 siRNA for the Suppression of Allogeneic Liver Transplant Rejection A Novel MD-MELD 3.0 Score Incorporating Donor Age and Muscularity Improves Early Mortality Prediction After Transplantation Predictive Risk & Evaluation of Complexity (PRECISE-LDLT): A New Framework for Donor Graft Assessment in Living Donor Liver Transplantation Clinical Utility and Prognostic Value of Post-Transplant Tumor Molecular Profiling Normothermic Machine Perfusion of Explanted Human Metabolic Livers: A Proof of Concept for Studying Inborn Errors of Metabolism Textbook Outcomes in Robotic Hepatectomy: A Single-Institution Experience Association of Intraoperative Delta Carboxyhemoglobin Levels with Post-Liver Transplant Acute Kidney Injury
|
| 7:00 AM - 8:00 AM | Meet the Expert 3: One Liver, Two Paths—Live Donor Transplantation vs Split Liver Transplantation in Pediatric Patients | Living Donor Liver Transplantation: The Optimal Strategy for Timely Pediatric Transplantation Split Liver Transplantation: The Most Ethical and Efficient Use of Scarce Donor Organs |
| 8:15 AM - 9:15 AM | Rising Star Award Session |
Mentor: Jeroen de Jonge Mentor: Qi Ling Mentor: Hideki Ohdan Mentor: Yuan Liu |
| 9:15 AM - 9:45 AM | Presidential Address | |
| 9:45 AM - 10:45 AM | State of the Art Lecture I | Transplant Oncology: Where Surgical Excellence Meets Cancer Science |
| 10:45 AM - 11:15 AM | Morning Break | |
| 11:15 AM - 12:30 PM | Maximizing Chances for Sick Children: Current Challenges and Innovations in Pediatric Liver Transplantation |
Eliminating Pediatric Waitlist Mortality: Lessons Learned from the Italian Mandatory Split Liver Policy Augmented and Mixed Reality in Partial Graft Matching Splitting on Machine Perfusion: Doubling Hope for Kids and Adults Liver Transplantation for Malignancy: Combination of Universal Practice Plus Innovations to Push the Boundaries |
| 11:15 AM - 12:30 PM | Building Translational Bridges Across Societies | Framing Remarks—How ILTS/AST/ASTS Can Jointly Lead the Next Decade of Collaborative Discovery and Clinical Translation Clinical Optimization Through Data-Driven Team Science Multicenter Pharmacotherapy Studies and Adaptive Trial Design Discussion 1: Operationalizing Cross-Society Collaboration Discussion 2: The Future of Cross-Society Team Science |
| 11:15 AM - 12:30 PM | Innovation in Education: Redefining Mentorship, Coaching, and Resilience in Transplant Training | Coaching for Growth – Fostering Personal Development in Transplant Training Strength in Numbers – Harnessing the Power of Lateral Peer Mentorship Mentorship as a Catalyst – Building Surgical Robotics Programs in Transplantation Beyond Burnout – Building Resilience in Early-Career Transplant Professionals |
| 11:15 AM - 12:30 PM | Concurrent Oral Session 1: Transplant Oncology |
Liver Transplantation for Portal Vein Tumor Thrombus in the Immunotherapy Era: Outcomes and Risk Stratification in a Multi-Institutional Study Post-Curative ctDNA Monitoring in Colorectal Liver Metastases Treated by Partial Hepatic Resection or Transplant Alpha‑Adrenergic Neuro-Immune Signaling Impacts Cancer Recurrence After Liver Transplantation Steatotic Grafts Synergize with Cold Ischemia Injury to Increase the Risk of Hepatocellular Carcinoma Recurrence After Liver Transplantation External Validation and Clinical Utility of the TRAIN-AI Model for Predicting Post-Transplant Recurrence of Hepatocellular Carcinoma Impact of Hierarchy in Locoregional Therapy in Liver Transplantation for Hepatocellular Carcinoma: A 24-Year Monocentric Analysis Six-Month Sustained Disease Control Selects HCC Patients Beyond the Milan Criteria for Liver Transplant with Comparable Oncologic Outcomes: An International Multicenter Cohort Study (TORCH-2401) |
| 11:15 AM - 12:30 PM | Concurrent Oral Session 2: Comorbidities and Liver Transplantation Outcomes |
Multidimensional Frailty Assessment of Liver Transplant Recipients with Long-Term Follow-Up (>20 Years): An ELITA/ELTR Study Development of a New Machine Learning Model to Predict Hepatocellular Carcinoma Recurrence After Liver Transplantation Prediction of Early Allograft Failure Risk After Liver Transplantation Using Interpretable Machine Learning with External and Prospective Validation Evaluation of Clinical Outcomes for Normothermic Machine Perfusion Versus Static Cold Storage in Liver Graft Preservation: Results from a Modelling Study Comprehensive Complications Index and Costs of Liver Transplantation: Validating a New Tool for the Estimation of Post-Transplant Costs Based on Patient-Specific Morbidity Socioeconomic and Regional Predictors of Survival Among Steatotic Liver Disease Transplant Recipients (2002–2024) |
| 11:15 AM - 12:30 PM | Round Table: Four Short Talks Followed by a Panel Discussion |
Do I Need Prothrombin Complex Concentrates? Do I Need Fibrinogen Concentrates or Factor XIII? DOACs in Liver Cirrhosis: Game Changer or High-Risk Gamble? Panel Discussion – All Speakers and Moderators |
| 12:30 PM - 1:45 PM | Lunch Break | |
| 12:45 PM - 1:45 PM | Industry Symposia | |
| 1:45 PM - 3:00 PM | To Err Is Human: But the Mechanisms of Graft Injury and Rejection Are More Translational? |
Immune Ecosystem Remodeling Across the Spectrum of Cholangitis 3D Tissue Modeling and Its Role in Improving Post-Transplant Injury Tackling Rejection at the Molecular Level Can Modifying Organs to Reduce the Risk of Rejection Be a Reality? The Role of Machine Perfusion |
| 1:45 PM - 3:00 PM | Concurrent Oral Session 4: Selection Criteria, Patient Selection, and Organ Allocation |
Bridging Global Gaps in Liver Transplant Outcome Prediction According to Donor and Recipient Factors and Risk-Mitigation Strategies: The Global Improvement Study MELD 3.0 Demonstrates Improved Discrimination for Organ Allocation in Alcohol-Associated Liver (ALD) Diseases but Not Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD) or Hepatitis C (HCV) Validation of Ontario Criteria for Patients Transplanted with Hepatocellular Carcinoma and Proposal of Revised Criteria Donor Serum FMN Reflects Mitochondrial Injury and Predicts Outcomes After Liver Transplantation: A Metabolic Donor Signature of Graft Quality Assessing Durability of Diet and Lifestyle-Based Weight Loss Interventions in Living Liver Donors After Donation in a U.S.-Based High-Volume Living Donor Liver Transplant Program |
| 1:45 PM - 3:00 PM | Comprehensive Peri-Operative Optimization of Liver Transplantation Candidates |
Preoperative Prehabilitation: Exercise and Nutritional Therapies How to Detect and Manage the Failing Graft: Which Treatment to Initiate (Especially Extracorporeal Therapies) and When to Retransplant, or Not Disparity in the Management of DCD Donors Across the World Perioperative ECMO for Liver Transplantation: Preventing Catastrophe or Introducing New Risks? |
| 1:45 PM - 3:00 PM | Managing That ‘Super Sick Patient’ as a Bridge to Liver Transplantation |
Critical Care Management and Optimization of the ACLF-3 Debate: Transplanting Through Infection/Sepsis (PRO) Debate: Transplanting Through Infection/Sepsis (CON) Global Access and Allocation Approaches to Impact Disincentives Q&A |
| 1:45 PM - 3:00 PM | Concurrent Oral Session 3: Donation After Circulatory Death and Machine Perfusion |
FMN Release During DHOPE Is an Early Predictor of Viability Assessment After Sequential Controlled Oxygenated Rewarming and NMP in Extended-Criteria DCD Livers Outcome of Dual Hypothermic Oxygenated Machine Perfusion Versus Abdominal Normothermic Regional Perfusion in Donation After Circulatory Death Liver Transplantation Microbiological Profile and Clinical Impact of Liver Graft Perfusion Fluid Cultures in a HOPE/D-HOPE Liver Transplantation Program in Latin America A Multicentre Comparative Analysis of Dual and Portal Hypothermic Oxygenated Perfusion in Liver Transplantation The Value of Flavin Mononucleotide (FMN) Measurement During Normothermic Machine Perfusion Graft Viability Assessment Continuous Multiparametric Monitoring of Donor Livers During Normothermic Perfusion |
| 1:45 PM - 3:00 PM | Implementing Change and Managing Resources: Can We Do Both? |
Global Differences in Liver Transplant Reimbursement: Impact of Inequity on Patient Care Cost of Implementing Innovation: Can We Afford What Is Next? AI in Liver Transplantation: How Will It Change What We Do? |
| 3:15 PM - 4:30 PM | Progress in Ex Vivo Machine Perfusion Techniques in Liver Transplantation: New Developments, Challenges, and Future Directions |
Setting the Stage—Existing Standards in Machine Perfusion in Liver Transplantation Viability Biomarkers: Current Status and Future Developments Long-Term Machine Perfusion—How Far Are We? Is Normothermic Regional Perfusion Alone Sufficient to Improve the Outcome of DCD Liver Transplantation? Debate—Pro Is Normothermic Regional Perfusion Alone Sufficient to Improve the Outcome of DCD Liver Transplantation? Debate—Contra |
| 3:15 PM - 4:30 PM | Vanguard Flash e-Poster: Session 2 |
Prospective Validation of a Novel Algorithm for Liver Transplantation in Children with Langerhans Cell Histiocytosis Liver Transplantation for Cholangiocarcinoma: A Multicenter Retrospective Analysis of 5-Year Survival Evaluation of siRNA LNP Therapy to Modulate PAI1 to Decrease Venous Thrombotic Risk After Liver Transplantation Intraoperative Cerebral and Somatic Oxygen Saturation Monitoring as Predictors of Postoperative Complications in Liver Transplantation: An Observational Study Body Composition Abnormalities and Post-Transplant Prognosis in Hepatocellular Carcinoma Liver Transplantation: A Multi-Task Clinical Surrogate Model BERGRAFT: Enabling a Safe Local Preservation Strategy for On-Demand Vascular Homografts in Transplantation and Advanced HPB Surgery |
| 3:15 PM - 4:30 PM | Swiss Transplant Session |
Short Introduction/Background on the Swiss Transplant Cohort Influence of Sex and Gender of the Donor and the Recipient on Infectious Complications Post-Liver Transplantation Long-Term Impact (10 Years) of Infectious Complications Post-Liver Transplantation Hypothermic Oxygenated Perfusion (HOPE) in Liver Transplantation |
| 3:15 PM - 4:30 PM | Concurrent Oral Session 6: Anesthesia, Critical Care Medicine, Acute Liver Failure |
Coagulation Imbalance and Mortality in Acute-on-Chronic Liver Failure: The Prognostic Role of Factor VIII, VWF and Global Coagulation Deficits External Oblique Intercostal Plane Block Versus Epidural for Live Open Donor Hepatectomy - A Randomised Controlled Trial Re-Transplantation Following Early Non-Function After Liver Transplantation: A Retrospective Multicenter Study Acute Kidney Injury Post Liver Transplant With Grafts Treated by Hypothermic Machine Perfusion: From Biology to Surgical Aspects Efficacy of Albumin Infusion for Hypoalbuminemia in Post-Operative Period in Living Donor Liver Transplantation - An Open Label Randomised Controlled Trial Clinical Implications of Postoperative Troponin Elevation Following Liver Transplantation: A Retrospective Cohort Study Normothermic Machine Perfusion Attenuates Peri-Implantation Inflammatory Responses in Liver Transplantation: A Prospective Pilot Study |
| 3:15 PM - 4:30 PM | What We Still Get Wrong in LDLT: Lessons from Experience, Not Textbooks |
We Still Get Patient Selection Wrong We Still Get Inflow Modulation Wrong (Small-for-Size) We Still Get Inflow Modulation Wrong (Large-for-Size) We Still Get Training and Standardization Wrong We Still Get International Comparison Wrong |
| 3:15 PM - 4:30 PM | Concurrent Oral Session 5: Basic Science, Translational Research, and Tolerance Induction I |
XCR1+ Conventional Dendritic Cells Interact with Macrophages via APOE-TREM2 to Promote Liver Regeneration Remodeling of the Intrahepatic Immune Niche in Donation After Circulatory Death Liver Grafts Metabolomic-Based Analysis of Ischemia-Reperfusion Mechanisms After Donor Warm Ischemia and Normothermic Regional Perfusion: A Preclinical Porcine Study Single-Cell RNA Sequencing Profiling of Human Livers During Normothermic Machine Perfusion Reveals Molecular Differences Between Steatotic and Non-Steatotic Donor Livers Prolonged HOPE Preserves Mitochondrial Function and Enables Logistical Flexibility in Liver Transplantation Gene-Based Methods for HLA Class I Suppression Aimed at Prolonging Liver Transplant Longevity Ex Vivo Normothermic Machine Perfusion as a Platform to Evaluate Lipid Nanoparticle-Mediated Transfection in Diseased Human Livers |
| 3:15 PM - 4:30 PM | Personalized Approaches in Liver Transplantation - AI |
AI-Driven Dynamic Risk Prediction in End-Stage Liver Disease: Beyond MELD for Transplant Listing Machine-Learning–Based Donor–Recipient Matching: Predictive Modelling for Graft Survival and Early Allograft Dysfunction AI-Assisted Selection for LDLT vs DDLT: Predictive Models for Optimal Pathway Allocation |
| 4:30 PM - 5:00 PM | Afternoon Break | |
| 5:00 PM - 6:15 PM | Liver Transplant Without Borders | From Journal to Bedside
Social Media Masterclass for Transplant Professionals Combating Misinformation in Transplant Medicine Strengthening Our Society: Membership Value and Communication Channels Connecting & Growing the Global ILTS Community – Panel Discussion |
| 5:00 PM - 6:15 PM | Evolving Infectious Risks and Innovations in Transplantation |
Donor-Derived Infections in the Era of Expanding Donor Pools: Lessons from HCV, HBV, and Beyond Antimicrobial Stewardship and Microbiome Preservation in Liver Transplantation Emerging Infectious Threats in Transplantation Hepatitis E Virus in Solid Organ Transplantation |
| 5:00 PM - 6:15 PM | Diagnosis to Transplantation in Cholangiocarcinoma |
AI vs. Imaging in Cholangiocarcinoma: Is There a Role for Radiogenomics? Can Imaging Differentiate Between Small-Duct and Large-Duct Intrahepatic Cholangiocarcinomas and Combined HCC-CCA? Residual or Reaction? Avoiding Missteps in Perihilar Cholangiocarcinoma Follow-Up SIRT in Intrahepatic Cholangiocarcinoma |
| 5:00 PM - 6:15 PM | Standardizing Training in Liver Transplantation |
Establishing Surgical Transplant Foundation While Safely Adopting New Technologies Critical Criteria for Transplant Hepatology Training Program Path to Accreditation of Training in Liver Transplant Anesthesia Model That Works: Successful Training of Pediatric Transplant Professionals and Development of Mentorship Network |
| 5:00 PM - 6:15 PM | Vanguard Surgical Videos | |
| Friday, May 8, 2026 | ||
| 7:00 AM - 8:00 AM | Meet the Expert 9: Post-Transplant Malignancies: Prevention, Early Detection, and Diagnosis | Identifying Risk Factors for Post-Transplant Cancer Mandatory Post-Transplant Cancer Screening |
| 7:00 AM - 8:00 AM | Vanguard Grand Rounds | |
| 7:00 AM - 8:00 AM | Meet the Expert 10: Building the Program Safely: Switching to Minimally Invasive Living Liver Donation | Tips and Tricks for Safe Laparoscopic Living Donor Liver Donation Tips and Tricks for Safe Robotic Living Donor Liver Donation |
| 7:00 AM - 8:00 AM | Meet the Expert 8: Navigating Complexity: Radiological and Surgical Approaches to Splenomesenteric Vein Thrombosis | Surgical Approaches to Splenomesenteric Thrombosis Radiological Approaches to Splenomesenteric Thrombosis |
| 7:00 AM - 8:00 AM | Meet the Expert 6: Managing Chronic Rejection: From Prevention to Treatment. |
Clinical Management of Chronic Rejection: Optimizing Immunosuppression and Monitoring Strategies |
| 7:00 AM - 8:00 AM | Vanguard Flash e-Poster Session 3 |
Excluding Ascites from the GEMA-Na Score Does Not Impact Outcome Predictions in Liver Transplant Candidates Robotic Versus Open Hepaticojejunostomy for Biliary Reconstruction Following Liver Transplantation Improved Evaluation for Donors for Liver Transplantation Using a Set of Three MicroRNAs Assessment of Right Ventricular Reserve in Liver Transplant Candidates with Pulmonary Hypertension Esterase-Responsive Degradable Antimicrobial Agents for the Treatment of Multidrug-Resistant Bacterial Infection Post-Transplantation Outcomes of Conversion to Everolimus Monotherapy in Steroid-Free Immunosuppression Following Liver Transplantation for Hepatocellular Carcinoma: A Single-Center Experience |
| 7:00 AM - 8:00 AM | Meet the Expert 7: Managing Obesity Across the Liver Transplant Journey: From Candidate Selection to Long-Term Care | Bariatric Surgery in Liver Transplantation: Timing, Techniques, and Outcomes |
| 8:00 AM - 9:15 AM | Plenary Abstract Session |
Targeting Tumoral Fatty Acid Desaturase 1 Empower IL-15-Armed GPC3-CAR-T Therapy in Hepatocellular Carcinoma Clinical Features and Long-Term Outcomes of Patients with Complete Immunosuppression Withdrawal After Liver Transplantation: A Multicentre, Worldwide Study Non-Vascular, Non-Cirrhotic Portal Hypertension Following Liver Transplantation Is Largely Caused by Combination of Portosinusoidal Injury and Allograft Rejection Auxiliary Partial Orthotopic Liver Transplantation Provides Durable Recovery in Pediatric Fulminant Hepatic Failure: Multicenter Experience in Children <10 Years Towards Time-Unlimited Liver Preservation: Key Steps in Advancing Long-Term Ex Vivo Normothermic Machine Perfusion from Days to 7 Weeks From National Policy to Clinical Practice: Early Experience with a Structured Prehabilitation and Rehabilitation Pathway in Liver Transplantation Off-the-Shelf CAR-T Cells Resistant to Immunosuppression for Cancer Therapy in Transplant Recipients |
| 9:15 AM - 9:30 AM | Society Awards | |
| 9:30 AM - 10:15 AM | State of the Art Lecture II | New Frontiers in Liver Xenotransplantation: Progress, Promise, and Pitfalls |
| 10:15 AM - 10:45 AM | Morning Break | |
| 10:45 AM - 12:00 PM | Novel Bioengineering Modalities in the Mechanistic Study and Therapeutics Development for Transplantation |
Bioengineering Approaches for Transplant Oncology and Immunology Refining Organoid to Be Structural Complexity and High-Throughput Approach for Regenerative Medicine Employing Human 3D Tissue Models to Delineate Immune Mediated Liver Disease Pathways Microscale Biofabrication of Magnetic Navigated Robot for Cancer Treatment and Tissue Repair |
| 10:45 AM - 12:00 PM | From Discard to Transplant: Global Strategies and Machine Perfusion to Expand the Liver Donor Pool |
Reconditioning High-Risk Grafts: Advances in Prolonged and Normothermic Machine Perfusion Engineering Better Grafts: Defatting, Splitting, and Immune Modulation on Perfusion Platforms Is There a Role for Machine Perfusion in LDLT? |
| 10:45 AM - 12:00 PM | Harnessing Collaboration Between ILTS and APASL on Liver Transplantation |
How APASL Guidelines on Management of ACLF Have Changed Management in the Asia Pacific Region Reversibility of Cirrhosis – When and How? Its Impact on Liver Transplantation The Evolving Trends of Liver Transplant Oncology in the Asia Pacific Region |
| 10:45 AM - 12:00 PM | Concurrent Oral Session 9: Pediatrics |
Expanding Boundaries in Pediatric Liver Transplantation Through Multimodal Perfusion Technologies: A 7-Year Experience The Application of Hypothermic Machine Perfusion in Challenging Paediatric Liver Transplantation: Growing Experience of Two Italian Centres Portal Vein Thrombosis in Pediatric Liver Transplantation With Technical Variant Grafts: An International Multicentre Analysis of Risk and Prognostic Factors The Role and Mechanism of EBV-Encoded miR-BHRF1-2 in Promoting the Occurrence and Development of PTLD After Pediatric Liver Transplantation by Promoting Cholesterol Metabolism and Activating the PI3K–AKT–mTOR Pathway MZB1 May Represent a New Biomarker and Replacement for C4D Staining for Antibody-Mediated Rejection in Pediatric Liver Transplantation Hepatic Outcomes After Isolated Heart Transplant in Fontan Patients: A Single-Center Experience Focus on the Management of Anastomotic Biliary Stricture After S2–S3 Split Liver Transplant in Paediatric Patients: Proposal for a New Standardization of Therapeutic Management |
| 10:45 AM - 12:00 PM | Concurrent Oral Session 7: Immunosuppression and Infection |
Klebsiella pneumoniae Infection Primes Cross-Reactive CD8+ T Cells That Trigger T Cell–Mediated Rejection After Liver Transplantation Perfusate Microbiology Before and After Hypothermic Oxygenated Perfusion: A Missing Piece in Graft Assessment Targeted Immunomodulation in Post-Transplant Sepsis: Mechanistic and Clinical Insights From a Phase-Based Approach Integrating IgM-Enriched IVIG and Hemoadsorption Diagnostic Accuracy and Clinical Utility of Microbial Cell-Free DNA Metagenomic Next-Generation Sequencing in the Early Period After Liver Transplantation Comparative Performance of Different Machine Learning Models for Diagnosing Acute TCMR in LDLT Recipients Safety and Pharmacokinetic Properties of Anti-Intercellular Adhesion Molecule 1 (DNP007) |
| 10:45 AM - 12:00 PM | Concurrent Oral Session 8: Living Donor Transplantation |
Dynamic Bilirubin Kinetics Enable a Two-Tier Subclassification (B1/B2) Within SFSS Grade B After LDLT: A 13-Center ILDLT Group Study Robotic Donor Hepatectomy Is Associated With Superior Long-Term Outcomes Compared to Laparoscopic or Open: A Single-Center Prospective Registry Study of 2,102 Cases Short- and Long-Term Outcomes After Living Domino Liver Transplantation Using the VANGUARD Multicenter Study Project of ILDLT Group Clinical Feasibility of Living Donor Liver Transplantation in Patients With Acute-on-Chronic Liver Failure: An International Multicenter Study Graft-to-Recipient Weight Ratio, Small-for-Size Syndrome, and Graft Inflow Modulation: Insights From the International Living Donor Liver Transplant Registry (LDLTRegistry.org) Refinement of Surgical Technique of Robotic Donor Hepatectomy: Evolution Over 502 Cases First Study on Liver Transplantation for Acute-on-Chronic Liver Failure From India: An Indian Liver Transplant Registry (ILTR) Database Analysis |
| 12:15 PM - 1:15 PM | Industry Symposium | |
| 12:15 PM - 1:15 PM | Lunch Break | |
| 1:15 PM - 2:30 PM | Liver Transplantation for Alcohol-Related Disease: Barriers and Unmet Needs |
Global Differences in the Management of AH and Access to LT Treatment of AUD in the Setting of ALD Peri-LT: How Can We Improve It? Immunosuppression Regimen in LT Recipients With a History of Excessive Alcohol Consumption Length of Abstinence Before LT for ALD: Time for a Consensus? |
| 1:15 PM - 2:30 PM | Concurrent Oral Session 11: Advanced Liver Surgery | Prognostic Value of Personalized Tumor-Informed Circulating Tumor DNA Analysis in Patients With Resected Biliary Tract Cancer: Real-World Study Complex Liver Resection With Hypothermic Perfusion for Tumors Involving the Hepatocaval Confluence: A Large Single-Center Series Prophylactic Abdominal Drainage in Liver Transplant (DRALIT): A National, Multicentre, Open-Label, Randomised Controlled Trial From Hybrid to Fully Robotic Liver Transplantation: A Stepwise Institutional Approach Achieving Reproducible Outcomes With Deceased and Living Donor Liver Transplantation Sutureless Portal Vein Reconstruction in Porcine Orthotopic Liver Transplantation Using a Microvascular Coupler: A Randomized Study With AI-Assisted Histopathology Hypothermic Oxygenated Machine Perfusion in Liver Autotransplantation for Critically Located Tumors: A Single-Center Case Series |
| 1:15 PM - 2:30 PM | Concurrent Oral Session 12: Allied Health & Education |
GLP-1 Therapy Utilization and Impact of Frailty and Functional Status in Liver Transplant Patients Preventing Tragedy Through Timely Action: The Critical Role of Early Transplant Referral From Non-Transplant Centers in Fulminant Liver Failure National Transplant Surgery Mentorship Programme (NTSMP-UK): Early Implementation Outcomes and Engagement Analysis From the First Formal Pilot in UK Transplant Surgery Bootcamp to Bedside: Advancing Excellence in Transplant Education for APPs in Liver Transplantation Enhanced Long-Term Survival and Quality-of-Life Outcomes Following Liver Transplantation for Hepatopulmonary Syndrome: Five-Year Results From a Coordinator-Led Audit |
| 1:15 PM - 2:30 PM | Concurrent Oral Session 10: Basic Science, Translational Research, Tolerance Induction II |
Therapeutic Transplantation of Mesenchymal Stem Cell-Modified Hepatic Organoids Potentiates Angiogenesis and Regeneration in Steatotic Livers Post-Hepatectomy Single-Cell and Spatial Characterization of Liver Allograft Inflammation Using Imaging Mass Cytometry Small Extracellular Vesicle-Derived miRNAs From End-Ischemic Organ Preservation Solution Reprogram Endothelial Cells Toward a Profibrotic Phenotype and Trigger Hepatic Stellate Cell Activation The Next Generation of Long-Term Normothermic Machine Perfusion: Molecular Insights From Human Livers Perfused for Up to 7 Weeks High-Resolution Single-Cell Spatial Atlas Identifies an Intermediate Monocyte–CD8⁺ Effector T-Cell Axis Driving Allogeneic Liver Transplant Rejection Preoperative Gut Microbiome Predicts Multidrug-Resistant Infection in Living Donor Liver Transplant Recipients: A Multicenter Prospective Cohort Study Hepatocyte-Targeted CAR-Tregs Enhance Liver Homing, Persistence, and Control of Acute Immune-Mediated Liver Injury |
| 1:15 PM - 2:30 PM | Elevating Standards in Liver Transplantation for Children, Young Adults, and Small Adult Recipients |
Immunosuppression Minimization: From Childhood Through Adulthood Multimodal Management of the Liver Recipient in Transitional Age Innovation in Split Liver Transplantation: Machine Perfusion and Beyond Preventing Large-for-Size Syndrome: Graft Reduction and Modelling Strategies for Young Adults and Those With Below-Average Body Size |
| 1:15 PM - 2:30 PM | Transplantation in Critically Ill Patients with ALF or ACLF: Between Hope and Limitslant: Global Strategies and Machine Perfusion to Expand the Liver Donor Pool |
Transplanting in the ICU in ACLF: Balancing Individual Benefit vs. Social Justice Transplanting in the ICU in ALF: Balancing Post-Transplant Complications vs. Potential for Recovery Marginal Donors in ALF/ACLF: Timing vs. Organ Quality Intraoperative Practices in ALF/ACLF: Veno-Venous Bypass, IOCRRT |
| 2:45 PM - 4:00 PM | Is EDI A Thing of the Past? |
EDI: Dead or Alive? Pros EDI: Dead or Alive? Cons EDI: The Strategic Influence of Professional Societies Highlights ILTS Global Liver Transplant Mentorship Program |
| 2:45 PM - 4:00 PM | From Resection to Liver Transplantation: The Evolution of Robotic Liver Surgery |
Summary of Consensus Meetings, Including Living Donor Robotic Resection for Hilar Cholangiocarcinoma Robotic Liver Transplantation: A Step-by-Step Evolution, How to Implement? Robotic Troubles: Worst-Case Scenario Management of Issues on the Robot |
| 2:45 PM - 4:00 PM | The Fragile Balance: Navigating Risk, Rescue, and Recovery in Liver Transplant Care |
More Than Surgical Skill: The Impact of Anesthesia and Critical Care on Postoperative Outcomes Optimizing Post-Transplant Pathways: Can Routine ICU Admission Be Safely Avoided? Surgery in Complex Patients: Does Veno-Venous Bypass Offer a Benefit? How Soon Is Too Soon? Timing Liver Transplantation After Coronary Intervention |
| 2:45 PM - 4:00 PM | Concurrent Session 13 : Comorbidities and Liver Transplantation Outcomes II | Alcoholic Acute-on-Chronic Liver Failure vs Alcoholic Cirrhosis: Clinical Outcomes After Liver Transplantation. A Single-Center Experience Pulmonary Complications of Liver Disease and Portal Hypertension: Evolving Access and Outcomes in a Large Nationwide Cohort Over 15 Years Long-Term Cause-Specific Excess Mortality After Liver Transplantation: A Spanish Nationwide Standardized Mortality Ratio Analysis The “Fifty-Fifty” Score as an Early Predictor of Postoperative Complications and 90-Day Mortality After Liver Transplantation A Donor Risk Factor-Inclusive Machine Learning Equation for Predicting Cholangiocarcinoma Recurrence After Liver Transplantation Clinical Implications of Serum Anti-Integrin αvβ6 Antibody Expression in Liver Transplant Recipients With Primary Sclerosing Cholangitis Use of Reabsorbable Self-Expandable Biliary Stents in Liver Transplantation: A Solution to Early Biliary Complications |
| 2:45 PM - 4:00 PM | Vanguard Flash e-Poster Session 4 |
Optimizing HBV/HDV Prophylaxis After Living Donor Liver Transplant: Antivirals Alone or With Hepatitis B Immunoglobulin? Demography, Benchmarking, and Personalized Medicine: The I2 Score – A Simple, Novel Score to Characterize Immunosuppression Intensity Intraoperative Right Ventricular Systolic Function in Liver Transplantation Recipients: A Prospective Observational Study Using Transesophageal Echocardiography During Living Donor Liver Transplant Surgery Anatomical Variations of the Hepatic Artery in Liver Transplant Recipients and Donors at Fundación Santa Fe de Bogotá: Prevalence and Association With Clinical Outcomes (2008–2024) Rapid Adoption and Program Evolution in the First 120 Robotic Cases at a Transplant Institute
|
| 2:45 PM - 4:00 PM | Innovation in Cardiovascular Disease in Liver Transplantation |
HPS and PoPH in Pediatrics: When Can We Push, When Should We Hold Back? Machine Perfusion and Coronary Artery Disease: Is It Time to Revisit Our Approach? Medical Management of Cardiovascular Disease in the Pre- and Post-Transplant Period: What’s New? Innovations in Cirrhotic Cardiomyopathy Management in Peds and Adults |
| 2:45 PM - 4:00 PM | What Is Hot in Liver Transplant Immunology? |
Personalized Tacrolimus Dosing: Where Do We Stand? Molecular Subtypes of Rejection After Liver Transplantation: Prognostic and Therapeutic Implications Liver Transplant Immunology in Xenotransplantation Recurrence of Immune-Mediated Liver Diseases After Liver Transplantation |
| 4:00 PM - 4:30 PM | Afternoon Break | |
| 4:30 PM - 5:45 PM | Transplant Oncology 2026: Progress, Controversies, and Global Perspectives |
A 2026 Lens on Transplant Oncology: What’s New? Liver Transplantation for CRLM: The Do’s and Don’ts in Patient Selection Case 1: Advanced HCC With Vascular Involvement – Role of Downstaging, Immuno-Oncology, and Transplantation Case 2: Advanced Intrahepatic Cholangiocarcinoma – Role of Liver Transplantation: Where Do We Draw the Line? |
| 4:30 PM - 5:45 PM | Liver Transplantation in Resource-Constrained Environments: Adapting Global Trends to Regional Realities |
Developing Sustainable Liver Transplant Programs in Limited-Resource Regions Refining Allocation in Latin America: Which Score Best Predicts Waitlist Mortality? Strategies for Expanding the Donor Pool: Overcoming Technical and Logistical Barriers The MASLD Revolution: Reshaping Liver Transplant Activity in Latin America |
| 4:30 PM - 5:45 PM | Concurrent Oral Session 14: Donation after Circulatory Death and Machine Perfusion II |
Clinical Outcomes of Abdominal Normothermic Regional Perfusion Versus Sequential Hypo- and Normothermic Machine Perfusion: A Single-Center Comparison Development and Validation of a Continuous Real-Time Optical Sensor for Indocyanine Green Clearance Measurement During Ex-Vivo Perfusion of Human Livers Benefit of Hypothermic Oxygenated Machine Perfusion in Reducing the Incidence of T-Cell–Mediated Rejection in Patients With Autoimmune Liver Diseases Undergoing Liver Transplantation: A Single-Centre Experience Multicenter Assessment of Biliary Complications of Normothermic Regional Perfusion and Normothermic Machine Perfusion for Donation After Circulatory Death Liver Transplantation Validation of Mitochondrial Flavin Mononucleotide as a Predictor of Early Allograft Dysfunction and Kidney Failure During End-Ischemic Hypothermic Oxygenated Machine Perfusion Hypernatremic Donors in Deceased Donor Liver Transplantation: Impact of Normothermic Machine Perfusion on Recipient Outcomes Outcomes After Transplantation of Liver Grafts Donated After Euthanasia |
| 4:30 PM - 5:45 PM | Living Donor Safety in Liver Transplantation: Lessons, Risks, and Responsibilities |
Preoperative Donor Evaluation: Hepatologic Perspective Preoperative Donor Evaluation: Surgical Perspective Intraoperative Safety and Minimizing Morbidity Long-Term Donor Outcomes: Beyond the Operation |
| 4:30 PM - 5:45 PM | Concurrent Oral Session 15: Surgical Video for Technical Innovations |
Fully Robotic Dual-Graft Living Donor Liver Transplantation: Pushing the Limits of Minimally Invasive Techniques Robotic Donor Hepatectomy as Standard of Care Aids in Managing Complex Donor Anatomy, Enhances Donor Safety and Recipient Outcomes: An Experience of 500 Cases Establishment of a Robotic Liver Transplant Program: Technical Improvement and Outcome Analysis Pushing Boundaries: The Feasibility of Robotic Living Donor Liver Transplantation in a Pediatric Recipient Ex-Situ Liver With Inferior Vena Cava Resection and Autotransplantation With Interposition IVC Grafting for Hepatic Alveolar Echinococcosis Infiltrating the Vena Cava, Hepatic Veins, and Diaphragm Right Extended Hepatectomy With IVC and Hepatic Veins Resection With Ante-Situm In Situ Hypothermia in a POST-TEXT IV Hepatoblastoma |
| 5:45 PM - 6:45 PM | ILTS Awards and Townhall | |
| 7:30 PM | ILTS Networking Dinner | |
| Saturday, May 9, 2026 | ||
| 8:00 AM - 9:15 AM | Plenary Abstract Session 2 | Novel Use of Portoatrial Shunt During Liver Transplantation Outcomes of Kidney-Only Transplantation in Recipients with Advanced Liver Disease: A Matched Comparison to Simultaneous Liver–Kidney and Kidney-Only Transplants Similar Long-Term Liver-Related and Mortality Outcomes for Living Liver Donors Compared to the General Population Performance of the ICI-RETREAT Score for Post-Transplant Cancer Outcome Prediction in Hepatocellular Carcinoma: Insights from the Global LIFT-HCC Consortium Extended Hypothermic Oxygenated Perfusion in Paediatric Partial Liver Grafts: A Bicentric UK Experience Pre-Transplant and Early Post-Transplant Inflammatory Biomarkers (NLR, IL-6, Nucleosomes) Predict Infection and One-Year Survival After Liver Transplantation: A Prospective Ancillary Study of the EDMONHG Cohort Sequential NRP and Hypothermic Versus Normothermic Ex-Situ Perfusion in Extended Criteria DCD Liver Transplantation: A Randomized Prospective Trial |
| 9:15 AM - 10:00 AM | State of the Art Lecture III | |
| 10:00 AM - 10:30 AM | Morning Break | |
| 10:30 AM - 11:45 AM | Concurrent Oral Session 16: Late-Breaking Abstracts |
Clinical Insights and Spatial Proteomic Strategies for Optimizing AMR Diagnosis in Pediatric Liver Transplantation Mitigating Senescence-Induced Ischemia-Reperfusion Injury in Liver Grafts from Older Donors Using Dasatinib and Quercetin Extracorporeal Liver Support (ECLS) Using a Bioengineered Liver for the Treatment of Acute Liver Failure (ALF), Acute-on-Chronic Liver Failure (ACLF), or Alcohol-Associated Hepatitis (AAH): Results from a First-of-Its-Kind Phase I Clinical Trial Establishing Global Benchmark Standards for Pediatric Liver Transplantation: An International Multicenter Study Combined Histo-Biological Assessment as a Tool to Refine Diagnosis and Avoid Overtreatment of Early T-Cell–Mediated Rejection After Liver Transplantation |
| 11:45 AM - 12:45 PM | Best of ILTS | Best of ILTS: Surgery Best of ILTS: Hepatology Best of ILTS: Anesthesia and Critical Care Best of ILTS: Basic Science
|
| 12:45 PM - 1:15 PM | Closing Ceremony & Transition of Presidency | |